Citigroup Maintains Buy on Ascendis Pharma, Raises Price Target to $182
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz has maintained a Buy rating on Ascendis Pharma (ASND) and increased the price target from $146 to $182. This adjustment reflects a positive outlook on the company's future performance.
February 08, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst David Lebowitz reaffirmed a Buy rating on Ascendis Pharma and raised the price target from $146 to $182, indicating a bullish outlook on the stock.
The increase in price target by a reputable analyst such as David Lebowitz from Citigroup usually signals strong confidence in the company's future performance and growth prospects. This is likely to positively influence investor sentiment and could lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100